Lampalizumab

• CAT Number: I042418
• CAS Number: 1278466-20-8
• Molecular Weight: 143.8 (kDa)
• Purity: ≥95%

Lampalizumab (Cat No.: I042418) is a humanized monoclonal antibody fragment targeting complement factor D, a key enzyme in the alternative complement pathway. It was developed to treat geographic atrophy (GA), an advanced form of age-related macular degeneration (AMD). By inhibiting complement activation, lampalizumab aimed to slow retinal cell degeneration. Despite promising early-phase trials, later-stage clinical studies failed to demonstrate significant efficacy in reducing GA progression, leading to discontinuation. Nonetheless, lampalizumab contributed valuable insights into complement inhibition as a therapeutic strategy in AMD.

Reference

[1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475.
[Content Brief]

[2]. Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100(1):122-7.
[Content Brief]